Sales of Novo Nordisk A/S’s obesity drug Wegovy rocketed in the first quarter as manufacturing problems that had dented supply came to an end, but Eli Lilly and Company’s rival tirzepatide is becoming an increasingly tangible threat.
Novo’s Wegovy Excels But Lilly Rival Hot On Heels
Obesity Sales Up 107%
After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.
More from Earnings
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.